GenEdit is a next-generation genome editing company. We are developing non-viral delivery technologies for the CRISPR/Cas9 gene editing system that can safely and efficiently correct gene mutations in patients. CRISPR/Cas9 is a powerful genome editing tool that makes therapeutic gene editing possible. It is easier to use, faster, and more accurate than previous gene editing techniques and thus has the potential for a wide range of therapeutic applications. In particular, CRISPR/Cas9 gene editing has the potential to treat a variety of incurable genetic diseases. However, current CRISPR delivery methods rely on viruses and are problematic due to viral-induced toxicity and prolonged Cas9 exposure, increasing off-target effects. A non-viral CRISPR/Cas9 delivery method is needed. In addition, low efficiency levels achieved make it impossible to target certain diseases. GenEdit's novel CRISPR delivery technology has the potential to be a platform delivery system for a broad range of genetic diseases. We also work on engineering of core components of CRISPR/Cas9 genome editing system to increase editing efficiency and enable targeted delivery.